Trial Profile
The Clinical Study of Structurally Optimized ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 26 Sep 2020
Price :
$35
*
At a glance
- Drugs ET 019002 (Primary)
- Indications B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 29 Aug 2018 New trial record